

Sergey N. Adamovich | Anna N. Mirskova | Rudolf G. Mirskov
Uwe Schilde

Synthesis and crystal structure of 1,4,10,13-tetraoxa-7,16- diazoniumcyclo-octadecane bis (4-chloro-2-methyl-phenoxyacetate)

Suggested citation referring to the original publication:
Chemistry central journal 5 (2011)
DOI <http://dx.doi.org/10.1186/1752-153X-5-23>
ISSN 1752-153X

Postprint archived at the Institutional Repository of the Potsdam University in:
Postprints der Universität Potsdam
Mathematisch-Naturwissenschaftliche Reihe ; 369
ISSN 1866-8372
<http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-400905>

PRELIMINARY COMMUNICATION

Open Access

Synthesis and crystal structure of 1,4,10,13-tetraoxa-7,16-diazoniumcyclo-octadecane bis(4-chloro-2-methyl-phenoxyacetate)

Sergey N Adamovich¹, Anna N Mirskova¹, Rudolf G Mirskov¹ and Uwe Schilde^{2*}

Abstract

The title compound was prepared by the reaction of 1,4,10,13-tetraoxa-7,16-diazacyclo-octadecane with 4-chloro-2-methyl-phenoxyacetic acid in a ratio of 1:2. The structure has been proved by the data of elemental analysis, IR spectroscopy, NMR (¹H, ¹³C) technique and by X-ray diffraction analysis. Intermolecular hydrogen bonds between the azonium protons and oxygen atoms of the carboxylate groups were found. Immunoactive properties of the title compound have been screened. The compound has the ability to suppress spontaneous and Con A-stimulated cell proliferation in vitro and therefore can be considered as immunodepressant.

Findings

Over many years the complexes of crown ethers (CE) with protonic acids and their metal salts attract the attention of scientific community due to both their peculiar molecular and stereoelectronic structure as well as the possibility of practical application [1,2]. The CE complexes enhance physiological activity of several chemical compounds. This fact is likely related to the ability of the complexes formed to overpass cellular and hema-toorganic barriers. In particular, specific complex-forming properties of CE allow them to be used for the drug design [2].

Recently, we have shown that tris-(2-hydroxyethyl) ammonium salts of organylheteroacetic acids [RYCH₂-COO]⁻·[NH(CH₂CH₂OH)]₃⁺, (R = Ar, Het; Y = O, S, SO₂), the cation of which has compact tricyclic atrane (2,8,9-trihydro-prototranic) structure [3], promoting to penetration of a matter through cellular membranes, represent a new class of biologically active compounds [4-9]. For example, tris(2-hydroxyethyl)ammonium salt of 4-chloro-2-methyl-phenoxyacetic acid exhibits adaptogenic, immunomodulating and antitumor properties. Besides, it effectively increases the resistance of animals to microwave electromagnetic radiation [7-9].

To search for new immunoactive congeners of this series, we have synthesized 1,4,10,13-tetraoxa-7,16-diazoniumcyclo-octadecane bis(4-chloro-2-methyl-phenoxyacetate) **1** and studied its immunoactive properties. Compound **1** was prepared in a yield of up to 98% by the reaction of 1,4,10,13-tetraoxa-7,16-diazacyclo-octadecane (1,10-diaza-18-crown-6 ether) with 4-chloro-2-methyl-phenoxyacetic acid in a ratio of 1:2 (Figure 1).

Compound **1** forms colorless crystals with m.p. 128°C. The structure of **1** has been proved by the data of elemental analysis, IR spectroscopy and NMR (¹H, ¹³C) technique. The IR spectra of **1** show broad vibration bands of ν(NH₂⁺) in the region 2800-2200 cm⁻¹. The stretching vibration bands of the O-C-O fragments of starting CE are high-field shifted from 1120, 1100 and 1067 to 1150-1090 cm⁻¹. In the IR spectrum, the bands of symmetric and asymmetric stretching vibrations of the carboxylate-ion are observed at 1580-1350 cm⁻¹.


The structure of compound **1** was established by crystal structure analysis. Crystal and experimental data are summarized in Table 1. The molecular structure with the atom labeling scheme is given in Figure 2. The packing diagram is shown in Figure 3. Selected bond lengths (Å), bond angles (°) as well as torsion angles (°) are listed in Table 2.

The asymmetric unit of **1** contains a half of the diprotonated 1,10-diazatetraoxa-18-crown-6 moiety and 4-chloro-2-methylphenoxyacetate as anion. The crown ether is centrosymmetric and the second half of the

* Correspondence: us@chem.uni-potsdam.de

²University of Potsdam, Institute of Chemistry, Karl-Liebknecht-Str. 24-25, D-14476 Potsdam, Germany

Full list of author information is available at the end of the article




cation is generated by inversion. 4-Chloro-2-methylphenoxyacetic acid is known as herbicide. In this molecule, the benzene ring and the oxoacetic acid side-chain are almost coplanar (CSD-Code CMPHAA) [10]. In contrast to this, in **1** the acetate moiety is torsioned around O1-C7 forming a torsion angle of $-79.7(2)^\circ$, whereas a torsion angle of only $-8.0(1)^\circ$ was found in the reference compound. Additionally, the distortion of the exo-C1 ring angles is more pronounced **1**: $115.4(1), 124.3(2)^\circ$; CMPHAA: $115.8(12), 122.0(13)^\circ$. The molecular packing is characterized by hydrogen bonds forming a ribbon-like structure along the crystallographic *b* axis. The geometry of the hydrogen bonds are given in Table 3.

Immunoactive properties of **1** have been screened. For example, the ability to impact on spontaneous and mitogen-stimulated (Con A, Sigma, 2 mkg/ml) proliferation of splenocytes in mice in vitro (antiproliferative properties) have been studied. It has been found that compound **1** exerts a distinct influence on spontaneous and mitogen-stimulated proliferation of splenocytes. The ability to suppress spontaneous (up to 72%) and Con A-

Table 1 Crystal data and details of the structure solution and refinement

Empirical formula	$C_{15}H_{22}ClNO_5$
Formula weight	331.79
Temperature	210(2) K
Wavelength	0.71073 Å
Crystal system, space group	Triclinic, <i>P</i>
Unit cell dimensions	$a = 7.5342(6)$ Å $\alpha = 97.624(7)^\circ$ $b = 9.1935(8)$ Å $\beta = 93.340(6)^\circ$ $c = 12.8532(10)$ Å $\gamma = 108.945(6)^\circ$
Volume	$829.73(12)$ Å ³
Z, Calculated density	2, 1.328 g/cm ³
Absorption coefficient	0.252 mm ⁻¹
F(000)	352
Crystal size	1.5 × 0.6 × 0.15 mm
θ range for data collection	1.61 to 25.0°
Reflections collected/unique	5361/2738
Refinement method	Full-matrix least-squares on F^2
Data/restraints/parameters	2738/0/288
Goodness-of-fit on F^2	1.001
R indices [$I > 2\sigma(I)$; 2280]	$R1 = 0.0423, wR2 = 0.1110$
R indices (all data)	$R1 = 0.0495, wR2 = 0.1147$
Largest diff. Peak and hole	0.413 and -0.319 eÅ ⁻³



stimulated (up to 99%) cell proliferation of spleen in vitro in the dosage of 3-300 mkg/ml allows compound **1** to be considered as immunodepressant.

Experimental

IR spectra were recorded on a Varian 3100 FT-IR75 spectrophotometer. NMR spectra (ppm) were measured on a DPX 400 instrument (400,13 MHz for ¹H and 101,62 MHz for ¹³C) in D₂O or methanol D₄ at 25°C. Reflections were collected using a STOE Imaging Plate Diffraction System (IPDS-II) at 210 K. The structure was solved by direct methods as implemented in the program SHELXS-97 [11]. The refinement was carried out using SHELXL-97 [12]. All the non-hydrogen atoms were refined anisotropically. The hydrogen atoms were located from the difference Fourier map and refined isotropically. For the visualisation of the structure the graphic programs DIAMOND [13] and ORTEP for Windows [14] were used. CIF data: Additional file 1. CCDC reference number: 812142.

Compound **1** was synthesized in the following manner. To a solution of 4-Cl-2-CH₃-C₆H₃OCH₂COOH (4.01 g, 0.02 mol) in MeOH (10 ml), was added dropwise a methanol (10 ml) solution of (CE) (2.62 g, 0.01 mol). The mixture was stirred at 25°C for 12 h.




Table 2 Selected bond lengths (Å), bond angles (°), and torsion angles (°)

C1-O1	1.369(2)	C4-C11	1.744(2)
C2-C9	1.502(2)	C7-O1	1.423(2)
C7-C8	1.523(2)	C8-O2	1.237(2)
C8-O3	1.249(2)	C10-O4	1.420(2)
C11-O4	1.419(2)	C12-O5	1.425(2)
C13-O5	1.405(2)	C14-N1	1.490(2)
C15-N1	1.500(2)		
O1-C1-C6	124.33(15)	O1-C1-C2	115.40(13)
O1-C7-C8	115.00(14)	O2-C8-O3	126.33(16)
O2-C8-C7	119.17(14)	O3-C8-O7	114.48(15)
O4-C10-C15 [†]	109.71(13)	O4-C11-C12	108.92(15)
O5-C12-C11	108.47(15)	O5-C13-C14	107.27(14)
N1-C14-C13	110.33(14)	N1-C15-C10 [†]	113.09(14)
C14-N1-C15	115.90(13)	C1-O1-C7	117.34(12)
C11-O4-C1	112.78(13)	C13-O5-C12	111.91(13)
O1-C1-C2-C3	-178.46(15)	O1-C1-C2-C9	-1.0(3)
C2-C3-C4-C11	-177.68(14)	O1-C7-C8-O2	-15.4(2)
O1-C7-C8-O3	166.31(14)	O4-C11-C12-O5	67.19(19)
O5-C13-C14-N1	-173.03(15)	C13-C14-N1-C15	-179.80(15)
C10 [†] -C15-N1-C14	-72.10(19)	C6-C1-O1-C7	5.5(2)
C2-C1-O1-C7	-174.16(16)	C8-C7-O1-C1	-79.74(19)
C12-C11-O4-C10	-167.40(15)	C15 [†] -C10-O4-C11	167.28(14)
C14-C13-O5-C12	-175.94(15)	C11-C12-O5-C13	179.36(16)

Symmetry code: $\ddagger 2-x, 2-y, 2-z$

The solvent was distilled in vacuum. The solid residue was repeatedly washed with ether and dried in vacuum to afford colorless powder (6.50 g, 98% yield), soluble in water and alcohol. Crystals suitable for X-ray diffraction were obtained by recrystallization of **1** from methanol (20°C). ¹H NMR (D₂O): 7.11-6.68 (m, 6H, C₆H₃O); 4.37 (s, 4H, CH₂COO); 3.63-3.56 (m, 16H, OCH₂, OCH₂-CH₂O); 3.15 (t, 8H, NCH₂); 2.13 (s, 6H, C₆H₃-CH₃). ¹³C NMR (D₂O): 176.80 (C=O); 156.04 (C₆H₄O); 140.87-111.56 (C₆H₃); 69.42 (OCH₂); 66.99 (CH₂COO); 65.29 (OCH₂CH₂O); 47.31 (NCH₂); 15.53 (C₆H₃-CH₃). Anal. Calcd. for C₃₀H₄₄Cl₂O₁₀N₂: C, 54.24; H, 6.63; Cl, 10.68; N, 4.22; Found: C, 54.54; H, 6.60; Cl, 10.68; N, 4.02.

Conclusions

1,4,10,13-Tetraoxa-7,16-diazoniumcyclo-octadecane bis(4-chloro-2-methyl-phenoxyacetate) **1** has been synthesized by the reaction of 1,10-diaza-18-crown-6 ether with 4-chloro-2-methyl-phenoxyacetic acid in a ratio of

Table 3 Hydrogen bond geometry (Å, °)

D-H...A	D-H	H...A	D...A	D-H...A
N1-H1...O2 [‡]	0.89(2)	1.83(2)	2.698(2)	165(2)
N1-H2...O3	0.93(2)	1.81(2)	2.708(2)	161(2)

Symmetry code: $\ddagger 2-x, 1-y, 2-z$

1:2 (yield 98%). The structure of **1** has been proved by the data of elemental analysis, IR spectroscopy, NMR (^1H , ^{13}C) technique and X-ray diffraction analysis. X-ray diffraction analysis has shown that the crown ether cation is centrosymmetric. The packing is characterized by a ribbon-like structure stabilized by hydrogen bonds. The title compound is a representative of a novel class of physiologically active compounds possessing immunodepressant properties. The investigation of physiological activity of **1** will be conducted in a new future.

Additional material

Additional file 1: Crystallographic information. Contains all relevant CIF information.

Acknowledgements

The authors acknowledge O. P. Kolesnikova for screening of immunoactive properties of compound **1**.

Author details

¹A.E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch, Russian Academy of Sciences, 1 Favorsky Str., 664033, Irkutsk, Russia. ²University of Potsdam, Institute of Chemistry, Karl-Liebknecht-Str. 24-25, D-14476 Potsdam, Germany.

Authors' contributions

SNA carried out the synthetic experiments and drafted the manuscript. ANM has formulated the research idea and prepared the manuscript draft version. RGM prepared the manuscript for submission and coordinated final formulation. US collected the X-ray data and performed the structure solution. Authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 15 February 2011 Accepted: 9 May 2011

Published: 9 May 2011

References

- Hiraoka M: *Crown Compounds: Their Characteristics and Applications* Amsterdam, Oxford, New York: Els. Scient. Publ. Comp; 1982.
- Bogatskii AV, Nazarov EI, Golovenko NYa: **Biological aspects of activity of crown ethers, criptands and their analogs.** *J of the DI Mendeleev all-union Chem Soc* 1985, **30**:593-599.
- Voronkov MG, Albanov AI, Aksamentova TN, Adamovich SN, Chipanina NN, Mirskov RG, Kochina TA, Vrazhnov DV, Litvinov MYu: **Tris(2-hydroxyethyl) ammonium Salts: 2,8,9-Trihydroprotatranes.** *Russ J Gen Chem* 2009, **79**:2339-2346.
- Voronkov MG, Mirskova AN, Levkovskaja GG: **Carcinostatic, Protective, and Adaptive Activities of Tris-(2-Hydroxyethyl)Ammonium Salts of Arylheteroacetic Acids.** *Dokl Biologica Sciences* 2002, **386**:404-406.
- Kolesnikova OP, Kudaeva OT, Sukhenko TG, Limonov VL, Kozlov VA, Mirskova AN, Voronkov MG: **Trekrezan as a Modulator of Hemato- and Immunopoeses.** *Dokl Biologica Sciences* 2003, **391**:306-308.
- Mirskova AN, Levkovskaja GG, Mirskov RG, Voronkov MG: **Hydroxyalkylammonium Salts of Organylsulfanyl(sulfonyl)acetic Acids - New Stimulators of Biological Processes.** *Russ J Org Chem* 2008, **44**:1478-1485.
- Kolesnikova OP, Mirskova AN, Adamovich SN, Mirskov RG, Kudaeva OT, Voronkov MG: **Alkanolammonium Salts of o-Cresoxy and p-Chlorocresoxyacetic Acids as Immunopoesis Modulators and Cytostatics.** *Dokl Biologica Sciences* 2009, **425**:107-111.
- Voronkov MG, Sofronov GA, Starchenko DA, Adamovich SN, Mirskova AN: **Protective Properties of Chlorocresacine against Adverse Impact of Electromagnetic Radiation.** *Dokl Biologica Sciences* 2009, **428**:398-402.
- Mirskova AN, Adamovich SN, Mirskov RG, Voronkov MG: **Tris-(2-hydroxyethyl)ammonium 2-methyl- and 2-methyl-4-chlorophenoxyacetate serve as effective inhibitors of thrombocyte aggregation and antioxidants.** *Dokl Biologica Sciences (Engl. Transl.)* 2010, **433**:244-246.
- Smith G, Kennard CHL: **4-Chloro-2-methylphenoxyacetic acid (MCPA): C9H9ClO3.** *Cryst Struct Comm* 1981, **10**:295-299.
- Sheldrick GM: *SHELXS-97: Program for the Solution of Crystal Structures* University of Göttingen, Germany; 1997.
- Sheldrick GM: *SHELXL-97, Program for the Refinement of Crystal Structures* University of Göttingen, Germany; 1997.
- Farrugia LJ: **ORTEP-3 for Windows - a version of ORTEP-III with a Graphical User Interface (GUI).** *J Appl Cryst* 1997, **30**:565.
- Brandenburg K: *DIAMOND, Version 3.1* Bonn: Crystal Impact; 2005.

doi:10.1186/1752-153X-5-23

Cite this article as: Adamovich et al.: Synthesis and crystal structure of 1,4,10,13-tetraoxa-7,16-diazoniumcyclo-octadecane bis(4-chloro-2-methyl-phenoxyacetate). *Chemistry Central Journal* 2011 **5**:23.

Publish with **ChemistryCentral** and every scientist can read your work free of charge

"Open access provides opportunities to our colleagues in other parts of the globe, by allowing anyone to view the content free of charge."

W. Jeffery Hurst, The Hershey Company.

- available free of charge to the entire scientific community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
<http://www.chemistrycentral.com/manuscript/>


ChemistryCentral